The past decade has seen a significant interest in investigating the intracellular metabolism of cells of the immune system. This has increased the realization that immune cells endure metabolic reprogramming upon responding to pathogen-derived or inflammatory signals. More importantly, not only does this metabolic switch provide for the bioenergetic and biosynthetic demands but also it, in a highly specific manner, determines the cellular fate and function. In this review, we discuss the metabolic aspects that regulate the differentiation and function of myeloid cells, pivotal for both innate and adaptive immunity. The manipulation of these pathways can alter the function of these cells and therefore, could provide novel therapeutic approaches in cancer and other chronic inflammatory conditions.
Introduction
Immune cells can uniquely respond to pathogen-derived or inflammatory cues, a response that rapidly ends quiescence and drives new gene expression, phenotype, and functions. It is becoming increasingly clear that this shift into more differentiated cells is tightly paralleled and regulated by different metabolic pathways-mainly glycolysis, the TCA cycle (also known as the citric acid cycle or Krebs cycle), and/or OXPHOS-that support the bioenergetic and biosynthetic demands of the new activation programs. Importantly, each of these metabolic pathways results in highly distinct consequences on cellular function and fate. This process of metabolic reprogramming in immune cells is mostly instructed by critical receptor signaling events, together with sensing the availability of metabolites within themselves or in the surrounding microenvironment [1] [2] [3] [4] [5] . This review focuses on the metabolic alternations associated with myeloid cell subsets, including neutrophils, Mf, DCs, and MDSCs-cells crucial for both innate and adaptive immune responses. It is of a significant interest that the manipulation of metabolic processes can specifically modulate the function of these cells, thereby boosting or dampening the immune response. Therefore, a better understanding of cellular immunometabolism will likely provide novel therapeutic targets that can enhance the treatment of diseases, such as cancer, infections, and autoimmunity.
AN OVERVIEW OF CELLULAR METABOLIC PATHWAYS
Cells of the immune system use different energy metabolic pathways to produce ATP to support cellular functions and survival and to synthesize intermediates allowing for cellular growth and proliferation [1, 3] . Three integrated metabolic pathways play a key role in fulfilling these bioenergetics needs: glycolysis, the TCA cycle, and OXPHOS ( Fig. 1) . Whereas glycolysis occurs in the cytosol, the TCA cycle and OXPHOS are limited to the mitochondria. Glycolysis begins with the uptake of glucose from the external environment through glucose transporters, after which, glucose is phosphorylated to G6P by hexokinases. During the glycolytic pathway, G6P is processed to pyruvate, reducing NAD + to NADH and yielding 2 molecules of ATP. G6P can also enter the PPP, a spinoff of glycolysis that generates reducing equivalents of NADPH necessary for the microbicidal mechanisms regulated by NOX and riboses essential for nucleotide synthesis. Under normoxia, glycolysis-derived pyruvate is converted into acetyl-CoA, which is oxidized in the TCA cycle, generating NADH and flavin adenine dinucleotide H2, which transfer electrons to the ETC to fuel OXPHOS and more efficiently produce ;30-36 molecules of ATP per a molecule of glucose. On the contrary, under hypoxia, pyruvate is diverted mainly into lactate, which exits the cell, and NAD + , which maintains the glycolytic flux. In some cases, however, cells rely on glycolysis to produce ATP even under aerobic conditions, which is referred to as aerobic glycolysis or the Warburg metabolism [6, 7] . Cells can also use other nutrients, such as glutamine through glutaminolysis and fatty acids through FAO, to support the TCA cycle and fuel the subsequent reactions of OXPHOS (Fig. 1) . By means of glutaminolysis, glutamine is converted to glutamate and further to a-ketoglutarate, which enters the TCA cycle. Ultimately, glutamine is either fully oxidized to support ATP production or used to replenish citrate for fatty acid synthesis. On the other hand, FAO, which yields acetyl-CoA to sustain the TCA cycle and OXPHOS, can facilitate the generation of substantial amounts of ATP (over 100 ATP molecules per a molecule of palmitate). Thus, besides the nutrient catabolism, the glycolytic pathway and TCA cycle can provide biosynthetic intermediates to support the generation of riboses, fatty acids, and amino acids (termed cataplerosis); nonetheless, the sustenance of these critical energy-producing pathways is met by an increased flux of nutrients (termed anaplerosis) [1, 3] . Taken together, cells, to different degrees, can generate ATP by choosing among several interconnected metabolic pathways. In the immune cells, this metabolic regulation can be dependent on the nutrient and oxygen availability and controlled by growth factors and cytokines, as well as important receptor signaling events, such TLRs.
IMMUNOMETABOLISM OF NEUTROPHILS
Neutrophils are short-lived granulocytes that provide the first line of defense of the innate immune system during microbial Figure 1 . An outline of the primary energy metabolic pathways. Cells produce ATP, the currency of cellular energy, using 3 main interconnected metabolic pathways: glycolysis, the TCA cycle, and OXPHOS. Three other pertinent biochemical pathways-the PPP, glutaminolysis, and FAO-are also depicted.
(continued from previous page) GCN2 = general control nonderepressible 2, GVHD = graft-versus-host disease, HADHA = 3-hydroxyacyl-CoA dehydrogenase, HIF-1a = hypoxiainducible factor 1a, IRF = IFN regulatory factor, Irg1 = immunoresponsive gene 1, L-PFK2 = liver-type phosphofructokinase 2, M-MDSC = monocytic myeloid-derived suppressor cell, M1 = classically activated Mf, M2 = alternatively activated Mf, MDSC = myeloid-derived suppressor cell, mTOR = mammalian target of rapamycin, mTORC2 = mammalian target of rapamycin complex 2, NET = neutrophil extracellular trap, NLRP3 = nucleotidebinding oligomerization domain-like receptor family, pyrin domain-containing 3, NOHA = N v -hydroxy-arginine, nor-NOHA = N v -hydroxy-nor-arginine, NOX = NADPH oxidase, OXPHOS = oxidative phosphorylation, PD-L1 = programmed cell death ligand 1, PFK2 = phosphofructokinase 2, PFKFB = 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, PGC-1 = peroxisome proliferatoractivated receptor-g coactivator 1, PMN-MDSC = polymorphonuclear myeloid-derived suppressor cell, PNT = peroxynitrite, PPAR = peroxisome proliferator-activated receptor, PPP = pentose-phosphate pathway, RNS = reactive nitrogen species, ROS = reactive oxygen species, SDH = succinate dehydrogenase, TAM = tumor-associated Mf, TLRL = TLR ligand, TRAF6 = TNFR-associated factor 6, T reg = regulatory T cell, u-PFK2 = ubiquitous phosphofructokinase 2, XBP1 = X-box-binding protein 1 infections. They destroy invading pathogens by phagocytosis, production of ROS, and release of NETs-chromatin structures laden with antimicrobial molecules-in a process recently termed NETosis [8, 9] . Early studies have suggested that neutrophils primarily rely on glucose and aerobic glycolysis to support ATP generation and microbial killing [10, 11] . In keeping with this, murine and human neutrophils have a low mitochondrial mass and consume little or no oxygen. In addition, their oxygen consumption and ROS secretion essentially remain unchanged in response to mitochondrial respiratory inhibitors, indicative of a minimal role for OXPHOS [12] [13] [14] [15] . In contrast, pathogen sensing by neutrophils promotes their intake of glucose and also increases their oxygen consumption [16, 17] . This program is pivotal in supporting the oxidative burst in primed neutrophils. The PPP branch of glycolysis produces NADPH required for the NOX system that uses oxygen for the generation of microbicidal ROS. Moreover, the NET release, which has been found to be NOX dependent [18] , is also strictly dependent on the glycolytic flux [19] , thus further emphasizing the importance of glycolysis in the antimicrobial activity of neutrophils. Whereas they do not serve a role in energy metabolism, neutrophil mitochondria can still maintain their membrane potential through the glycerol-3-phosphate shuttle, thereby playing a significant role in the cellular redox status [20] . Following an oxidative burst, mitochondria lose their potential, leading to the release of cytochrome c and triggering apoptosis [13, 20] . The transcription factor HIF-1a, which can be activated by hypoxia or microbial infection, is a major regulator of the uptake and catabolism of glucose in neutrophils. Consequently, HIF-1a deficiency in neutrophils not only impairs glycolysis and ATP production but also decreases cell survival and diminishes the production of granule proteases and antimicrobial peptides, thus rendering mice more susceptible to bacterial infection [21] [22] [23] .
IMMUNOMETABOLISM OF Mf
Mf are a versatile cell population of the immune system that reside in virtually all tissues of the body. Mf play key roles in the host defense against infection and injury and contribute to tissue repair and homeostasis [24, 25] . These tissue-resident Mf originate from embryonic precursors and are maintained by local proliferation. However, in the course of inflammation, monocytes derived from bone marrow progenitors can further differentiate in tissues into Mf [26] [27] [28] [29] . A key contribution is that Mf can be polarized to distinct phenotypes in response to pathogen-derived cues. M1 Mf are induced by microbial stimuli, such as LPS, alone or in combination with other signals associated with infection, such as IFN-g and TNF-a. This program of activation results in inflammatory Mf that produce high levels of proinflammatory cytokines (such as IL-6, IL-12, and TNF-a) and ROS and RNS. Therefore, M1 Mf possess increased phagocytic and microbicidal activities. On the other hand, M2 Mf are promoted by the type 2 cytokines IL-4 and IL-13 and play crucial roles linked to anti-parasitic immunity, tissue repair, and angiogenesis [30] [31] [32] [33] . Another important consequence of Mf activation into M1 and M2 subsets is the differential arginine metabolism. M1 Mf express NOS2 that catabolizes arginine to NO, which participates in the cytotoxic mechanisms, in addition to citrulline generated as a byproduct. Alternatively, M2 Mf induce arginase 1 that metabolizes arginine to ornithine and urea. Ornithine is the precursor for the production of polyamines, which regulate cell proliferation and differentiation, and proline, which is critical for the synthesis of collagen, a primary protein in wound healing and fibrosis [34] [35] [36] . Of note, as discussed below, M1 and M2 Mf also have distinct metabolic profiles that clearly reflect the functions of each of these cell populations.
M1 Mf
M1 Mf primarily rely on Warburg metabolism in preference to OXPHOS to produce ATP, thus providing these cells with an energetic advantage when oxygen is limiting [37, 38] . The increased glycolysis in M1 Mf is driven by a switch in the expression of PFK2 from the L-PFK2 encoded by the PFKFB1 gene to the more active u-PFK2 isoform encoded by the PFKFB3 gene, which results in higher levels of fructose-2,6-bisphosphate and glycolytic flux [39] . In addition, M1 activation induced by LPS rapidly down-regulates the expression of CARKL, a sedoheptulose kinase converting sedoheptulose to sedoheptulose-7-phosphate. CARKL inhibits flux through the PPP, blocking the generation of NADPH (essential for ROS and NO production) and restraining glycolysis. Therefore, CARKL repression, following M1 Mf activation, drives the cellular redox state and effector functions [40] . Furthermore, like neutrophils, HIF-1a plays an essential role in the glycolytic pathway, both under normoxic and hypoxic conditions. Mf, deficient in HIF-1a, exhibit reduced glycolytic capacity and ATP production, hence resulting in the impairment of several energy-demanding processes, such as migration, TNF-a and NO production, and bactericidal activity [21, 22, 41] . HIF-1a can stimulate the aerobic glycolysis by inducing the expression of 2 enzymes: lactate dehydrogenase, which converts pyruvate into lactate, and pyruvate dehydrogenase kinase, which phosphorylates and prevents pyruvate dehydrogenase from using pyruvate to produce acetyl-CoA to fuel the mitochondrial TCA cycle [42, 43] . However, other important events associated with the glycolytic metabolism in M1 Mf are notably not dependent on HIF-1a. Among these HIF-1a-independent processes are ROS secretion and the expression of u-PFK2 rather than L-PFK2, indicating the involvement of other factors [22, 39] .
Another key feature of M1 Mf is the contribution of signals derived from their mitochondria to the metabolic and functional reprogramming of these cells. Mitochondrial ROS have been implicated in the ability of M1 Mf to kill intracellular bacteria. Specifically, the triggering of TLR1/2/4 signaling in Mf causes the mitochondria to engage with the phagolysosomes and produce ROS that are important for the bactericidal activity. This process involves the interaction of the TLR signaling adaptor TRAF6 with the protein ECSIT, which results in ECSIT ubiquitination and enrichment at the mitochondrial periphery and ultimately mitochondrial ROS production. Congruent with these findings, the depletion of TRAF6 and ECSIT or the reduction of mitochondria ROS via catalase expression impairs the bactericidal capacity of Mf [44] . Of interest, mitochondrial ROS support the production of proinflammatory cytokines, such as IL-1b, IL-6, and TNF-a, through inactivating MAPK phosphatases, thereby sustaining MAPK activity and promoting the inflammatory responses [45] . Furthermore, mitochondrial ROS serve a key role in the activation of the NLRP3 inflammasome, increasing the activation of caspase 1 and production of IL-1b, responses that are dependent on the mitochondrial voltagedependent anion channels [46] . Consistent with this, following mitochondrial ROS production, mitochondrial DNA is released into the cytosol in a fashion that depends on the NLRP3 inflammasome activation and augments the production of IL-1b. Thus, depletion of autophagic proteins increases the activation of the NLRP3 inflammasome and secretion of IL-1b [47, 48] . Moreover, metformin, which inhibits the activity of NADH: ubiquinone oxidoreductase (complex I), or rotenone, the specific complex I inhibitor, blocks the generation of ROS and IL-1b, thus implicating mitochondrial ROS in pro-IL-1b production [49] .
Importantly, the TCA cycle in M1 Mf is broken at two points: at the enzyme isocitrate dehydrogenase and then at the enzyme SDH, thereby resulting in the accumulation of citrate and succinate, respectively [50] . Interestingly, these two metabolites remarkably modulate the function of M1 Mf. On one hand, a citrate increase promotes the synthesis of itaconic acid, a metabolite produced via the decarboxylation of citrate-derived cis-aconitate by the enzyme encoded by Irg1. As itaconic acid inhibits isocitrate lyase-the key enzyme of the glyoxylate shunt that is critical for bacteria growing on fatty acids or acetate as the major carbon source-this metabolite has a microbicidal activity, limiting the growth of Salmonella enterica and Mycobacterium tuberculosis. Accordingly, Irg1-deficient Mf generate less itaconic acid and have an impaired anti-bacterial activity [51] . Additionally, citrate plays an important role in the synthesis of fatty acids, which sustain the production of proinflammatory PGs, and once shuttled into the cytosol via the mitochondrial citrate carrier, citrate is metabolized by citrate lyase into acetyl-CoA and oxaloacetate, NO and ROS precursors [52] . On the other hand, succinate induces the production of IL-1b through a mechanism involving HIF-1a stabilization, a signal that can be limited by inhibiting glycolysis with 2-DG [53, 54] . More recently, mitochondrial oxidation of succinate by SDH, coupled with mitochondrial hyperpolarization, has been implicated in mitochondrial ROS production and proinflammatory responses [55] .
M2 Mf
M2 Mf, unlike M1 counterparts, have a decreased glycolytic activity and rely on FAO and OXPHOS to meet their energetic essentials. M2 Mf express the PFKFB1 gene coding for the L-PFK2 that convert the glycolysis inducer fructose-2,6-bisphosphate to fructose-6-phosphate, thereby reducing the glycolytic rate [39] . M2 Mf also induce the expression of CARKL, a PPP inhibitor, and therefore, CARKL knockdown blocks the M2 polarization, while enhancing the glycolytic pathway and the production of proinflammatory cytokines, such as IL-6 and TNF-a [40] . Moreover, M2 Mf are characterized by an increased catabolism of glutamine to yield uridine diphosphate N-acetylglucosamine that is critical for the glycosylation of lectin/mannose receptors, typical M2 polarization markers. As such, glutamine deprivation or N-glycosylation inhibition reduces M2 polarization, suggestive of the role of glutamine metabolism in this process [50] .
M2 Mf exhibit an increased mitochondrial biogenesis and FAO in response to the type 2 cytokine IL-4. Therefore, the blocking of OXPHOS with the metabolic inhibitors oligomycin and carbonyl cyanide p-trifluoromethoxyphenylhydrazone diminishes M2 polarization. This reprogramming into oxidative metabolism is mediated through PGC-1b, an important regulator of oxidative metabolism genes, in a STAT6-dependent mechanism. In line with this, PGC-1b knockdown inhibits FAO and M2 markers, whereas its constitutive expression reverses this response [56] . More recent work investigating the source of fatty acids feeding the TCA cycle suggests that the uptake of triacylglycerols from the external environment through CD36, followed by their lipolysis by lysosomal acid lipase, is critical for M2 activation. Notably, inhibition of lipolysis restricts M2 function and blocks a therapeutic response to parasitic helminth infections [57] . Additionally, the nuclear receptors PPARg and PPARd, which play key roles in FAO regulation, are also induced by IL-4/STAT6 signaling and found to be crucial for the acquisition and long-term maintenance of M2 oxidative metabolism and alternative activation [58] [59] [60] . Furthermore, unlike M1 Mf, M2 Mf increase the phosphorylation of AMPK, which is reported to activate PGC-1a and promote the mitochondrial biogenesis and FAO [61, 62] . More recently, it has been shown that glucose metabolism contributes to M2 activation via sustaining fatty acid synthesis and FAO. The activation of mTORC2, involving PI3K and Akt, and IRF-4 critically mediates this glycolytic response. Consistent with this, the absence of mTORC2 signaling in Mf delays tumor growth but diminishes immunity against parasitic nematodes [63] .
Overall, these findings support the view that the bias toward a particular metabolic pathway directly influences the diverse functions of M1 and M2 Mf. On the one hand, glycolysis may be optimal for immediate oxidative bursts undertaken by M1 Mf as part of the first line of the innate immune defense. On the other hand, FAO may be better suited for the energetically demanding long-term M2 activation essential for clearing chronic parasitic infections. The majority of the Mf metabolism data are derived from murine studies, and limited information is available on human Mf. Similar to murine M1 Mf, human counterparts seem to up-regulate glycolysis and maintain a proinflammatory phenotype [64] . In fact, a recent study showed that M. tuberculosis infection reprograms the metabolism of human alveolar Mf and monocyte-derived Mf from OXPHOS to aerobic glycolysis. Inhibition of glycolysis minimized the levels of IL-1b, increased those of IL-10, and enhanced intracellular bacillary survival. This suggests that infection-elicited glycolysis can restrain the growth of M. tuberculosis, therefore highlighting the role of metabolic interventions in promoting the early clearance of the bacillus by Mf [65] . Although scant, available evidence suggests that OXPHOS and FAO do not operate in human M2 Mf [64, 66] , and such data remain to be confirmed, particularly in Mf associated with chronic inflammatory conditions. The delineation of these metabolic characteristics, especially in human Mf, has important therapeutic prospects. As mentioned in this section, it seems possible that the targeting of metabolic mediators, such as CARKL, TRAF6, ECSIT, and ROS, could switch Mf from M1 to M2 phenotype, thus controlling the immune response in conditions such as autoimmunity. Likewise, the targeting of CARKL, AMPK, and mTORC2 could potentially block immune suppression and induce anti-tumor immunity.
IMMUNOMETABOLISM OF DCs
DCs are the most specialized APCs that link innate and adaptive immune responses. They present pathogen-derived antigenic peptides and provide costimulatory molecules and cytokines crucial for the activation and differentiation of antigen-reactive T cell effectors. On the contrary to their immunogenic functions, DCs can be instructed to promote tolerogenic immune responses via T regs and other mechanisms [67] [68] [69] . DCs are heterogeneous and can be classified into a number of subpopulations with distinct phenotypes, functions, and tissue locations, including cDCs, Langerhans cells, monocyte-derived DCs, and plasmacytoid DCs [70, 71] . Despite the fact that our current knowledge of the metabolic pathways that control these multiple DC subsets in vivo is limited, recent reports still provide strong evidence that alternations in cellular metabolism can profoundly direct DC differentiation and functions.
DCs are found in almost all tissues of the body in a resting immature phenotype. However, cellular activation or maturation can be rapidly induced through triggering a variety of pattern recognition receptors, including TLRs, by pathogens or other danger signals, a process that allows DCs to become highly migratory and immunogenic. The early studies on DC metabolism have mostly examined cells generated by culturing bone marrow precursors in GM-CSF and then stimulated with TLRLs. During quiescence, these cells primarily use OXPHOS fueled by glucose. Interestingly though, DCs undergo a metabolic switch into aerobic glycolysis following activation by TLRLs. The significance of this cellular reprogramming is manifested by the results that the inhibition of glycolysis by 2-DG impairs DC maturation and function. Additionally, the glycolytic metabolism in DCs depends on the activation of both HIF-1a and PI3K/Akt pathways, indicating a possible role of mTOR downstream of PI3K/Akt [72, 73] . Although mTOR can directly regulate the activation of HIF-1a [74, 75] , the mTOR inhibitor rapamycin has been reported to exert both stimulatory and suppressive effects on murine and human DCs, largely depending on the time of treatment during the DC lifespan [76] [77] [78] . Conversely, this glycolytic response in DCs is antagonized by the induction of the OXPHOS mediator AMPK, which inhibits DC maturation [73] .
With these results in mind, the question then arose as to why mitochondrial OXPHOS is rapidly lost in TLR-triggered DCs. In a recent report, it has been found that in inflammatory DC subpopulations, such as in vitro-generated GM-CSF DCs and monocyte-derived DCs, the glycolytic switch is accompanied by a NOS2-mediated NO production that can directly inhibit the mitochondrial ETC in an autocrine/paracrine fashion [79] [80] [81] . Accordingly, these inflammatory DCs preferentially use glycolysis to preserve their capacity to produce ATP and survive when OXPHOS is diminished [81] . On the other hand, cDCs do not express NOS2 nor could NOS2 be induced in these cells by TLRLs or inflammatory cytokines. Therefore, unlike inflammatory DCs, cDCs do not undergo a metabolic reprogramming into glycolysis [81] . In contrast, another study has recently shown that TLR-induced type I IFNs, independently of NOS2, activate HIF1a, resulting in a metabolic switch from OXPHOS to glycolysis in cDCs, a process that is required for their maturation in vivo [82] .
Of note, during the early events of TLR-driven DC activation, OXPHOS is intact and predominantly supports ATP generation, despite the concomitant increase in the glycolytic rate [81, 83] . However, this rapid increase in glycolysis, which is NOS2 independent and does not provide another important source of ATP, is also crucial for the activation and function of inflammatory DCs, as well as cDCs [83] . Intriguingly, the early glucose intake fuels the de novo synthesis of fatty acids by generating NADPH via the PPP and by replenishing the TCA cycle-derived citrate that is exported from the mitochondria into the cytosol through the citrate shuttle Slc25a1. In turn, the de novo fatty acid synthesis allows for increasing the mass of the ER and Golgi, organelles necessary for the synthesis and secretion of proteins following TLR ligation. This early activation program is regulated by Akt-dependent induction of the rate-limiting glycolytic enzyme hexokinase 2 via increasing its association with the mitochondria, with TRAF family member-associated NF-kB activator-binding kinase 1 and IkB kinase e as the major drivers of Akt phosphorylation [83] . Altogether, these findings indicate that DCs, particularly inflammatory DCs and cDCs, via different mechanisms, can adopt the transition into aerobic glycolysis to support their maturation and immunogenic functions. Nevertheless, the metabolic pathways that control the phenotypic and functional aspects of other DC subsets remain elusive.
In contrast with the metabolism of immunogenic DCs, little is currently known of the metabolic dependency of antiinflammatory tolerogenic DCs. Tolerogenic DCs are immature or semimature, have a diminished costimulatory capacity, and promote T cell anergy [67, 84] . Recent evidence has pointed out that lipid metabolism may represent an important regulator of the differentiation and function of these immunoregulatory cells. Compared with proinflammatory mature DCs, tolerogenic DCs, generated in the presence of dexamethasone and vitamin D3, have an increased catabolic metabolism manifested by OXPHOS, FAO, and glycolysis, thus endowing these cells with the metabolic flexibility essential for maintaining ATP content. Importantly, FAO inhibition abrogates the T cell regulatory function of human tolerogenic DCs, suggesting their reliance on this pathway [85] . Congruent with these observations, activation of PPARg, an FAO integrator, reduces murine and human DC maturation and the ability to prime T cells [86, 87] , responses that are reversed in PPARg-deficient DCs [88, 89] . Likewise, lipid-laden, tumor-infiltrating DCs are known to impair antitumor T cell responses, contributing to tumor progression. Tumor-infiltrating DCs take up and accumulate different species of oxidized neutral lipids, such as triglycerides, cholesterol esters, and fatty acids, through the up-regulation of scavenger receptor A. These oxidized lipids render DCs less capable of crosspresenting tumor-associated antigens by decreasing the expression of peptide-MHC class I complexes on the cell surface [90, 91] . The normalization of the lipid content in DCs by the inhibition of de novo fatty acid synthesis restores the immunogenic function of DCs and improves the anti-tumor response of a cancer vaccine [90] . More recently, tumor-infiltrating DCs have been shown to display ER stress via the stress sensor inositolrequiring enzyme 1a, resulting in the constitutive activation of XBP1. XBP1-induced lipid biosynthesis and accumulation then inhibit DC proinflammatory functions, whereas XBP1 silencing reestablishes DC immunopotentiating activity and elicits therapeutic anti-tumor T cell responses [92] . Taken together, these findings make it conceivable to think of this lipid accumulation as a means to support FAO and oxidative metabolism in DCs with defective T cell stimulatory functions.
As outlined above, it is becoming clear that the activation and function of DCs are essentially controlled by their energy metabolism, thus paving the way for developing novel approaches to better use DCs as a potent therapeutic tool. The halting of the immunogenicity of DCs can be beneficial in regulating the immune response, for instance, to prevent posttissue transplant rejection. This could be achieved through the inhibition of glycolysis using glycolytic or HIF-1a inhibitors [93] [94] [95] or by promoting the catabolic lipid metabolism using dexamethasone, vitamin D3, or PPARg agonists [85] [86] [87] . On the other hand, the enhancement of DC functions still holds a great promise for maximizing the efficacy of cancer immunotherapy. As discussed, the targeting of the unbalanced lipid metabolism or ER stress in tumor-infiltrating DCs results in superior anti-tumor immunity [91, 92] . It will be exciting to test whether these interventions would synergize with others that prolong the survival of activated DCs, such as rapamycin [76] , to mediate better regression of different types of cancer.
IMMUNOMETABOLISM OF MDSCs
MDSCs rapidly expand during multiple chronic inflammatory conditions, including cancer [96, 97] , infections [98, 99] , trauma [100] , obesity [101, 102] , GVHD [103] , and autoimmune diseases [104] . These conditions are characterized by a sustained status of aberrant myelopoiesis, and therefore, MDSCs are a mixed population of myeloid progenitor cells whose normal development to mature myeloid cells, such as Mf, DCs, and neutrophils, is impaired. They comprise two major subsets: M-MDSCs and PMNMDSCs. In mice, M-MDSCs are CD11b [105] . More importantly, these cells potently suppress innate and adaptive immunity and, hence, are considered a therapeutic target in several disease scenarios. Numerous cancer-associated factors can mediate the expansion and immunoregulatory function of MDSCs. Among these factors, G-CSF and GM-CSF are two main regulators of MDSC development. Whereas G-CSF is critical for the mobilization and differentiation of bone marrow granulocytic progenitors within tumors [106] , GM-CSF, depending on the stimulus magnitude and context, can induce MDSCs both in vitro and in vivo [107, 108] . IL-1b also drives MDSCs, directly or indirectly, via promoting IL-6 production [109, 110] . Additionally, IL-4 and IL-13 promote MDSC-suppressive mechanisms via IL-4Ra-dependent STAT6 activation [111, 112] . Other proinflammatory danger signals, secreted largely by myeloid cells, such as S100A8/ A9 proteins and high-mobility group box 1, can also enhance MDSC trafficking and function by signaling through cell membrane receptors, such as TLRs and the receptor for advanced glycation end-products [113, 114] . Likewise, several transcription factors regulate MDSC accumulation and function. For instance, STAT1, activated by types 1 and 2 IFNs and IL-1b, mediates MDSC expansion and function (NOS2 and arginase 1) [115, 116] . Furthermore, the induction of STAT3 and STAT5 via G-CSF and GM-CSF, respectively, down-regulates IRF-8, which essentially drives MDSC accumulation [117] . STAT3 can also induce genes critical for several MDSC aspects, including their differentiation and proliferation (c-myc, cyclin D1, and S100A8/ A9) and suppressive function (arginase 1, NOX2 subunits p47 phox and gp91 phox , and C/EBPb) [118] [119] [120] [121] [122] . C/EBPb homologous protein, induced by tumor-derived ROS and RNS and regulated by activating transcription factor 4, promotes IL-6 production and activates C/EBPb, as well as STAT3, thereby mediating MDSC regulatory function [123] .
MDSCs induce immune tolerance using different mechanisms. They can directly deprive T cells of essential metabolites, including arginine, tryptophan, and cysteine, or alter T cell viability, migration, and activation. Besides, they can indirectly suppress T cells through promoting other tolerogenic immune cells, such as T regs and TAMs [96, 97, 124] .
The metabolic consumption of arginine via arginase 1 is one of the first T cell regulatory pathways described in MDSCs. PMN-MDSCs, the major source of arginase 1 in tumor bearers, can decrease the availability of extracellular arginine by arginine incorporation via the cationic amino acid transporter 2B or the secretion of arginase 1 [125, 126] . As a result of arginine starvation, T cells down-regulate the expression of CD3z, a hallmark of T cell dysfunction in cancer patients [127] . Nevertheless, arginine-deprived T cells exhibit a normal expression of early activation markers, such as CD25, CD69, and CD122, and IL-2 production, suggesting that arginine is not a requisite for these early T cell events [128] . Rather, arginine depletion arrests T cells in the G0-G1 phase of the cell cycle as a result of an impaired expression of cyclin D3 and cyclin-dependent kinase 4 through a decreased mRNA stability and diminished translational rate [129, 130] . Additionally, arginine deprivation in vivo impairs T cell responses as a result of a GCN2-dependent accumulation of MDSCs [131] . Accordingly, arginase 1 inhibitors, such as nor-NOHA and NOHA, reduce MDSC-suppressive activity and lead to T cell-mediated anti-tumor immunity [97, 125] . Consistent with these results, arginine has recently been found to be critical for T cell metabolic fitness and survival, and therefore, the increase of the intracellular arginine abundance in T cells before adoptive cellular therapy enhances their persistence and anti-tumor responses [132] .
Arginine catabolism to NO through NOS2 in M-MDSCs and NOS3 in PMN-MDSCs serves another key regulatory role in these cells [133] . NO has proapoptotic effects and can also suppress T cells by impairing the IL-2R signaling pathways Jak-3, STAT5, ERK, and AKT [134, 135] . On the other hand, MDSCs, via the NOX subunits p22 phox , p47 phox , and gp91 phox , produce ROS, such as superoxide and hydrogen peroxide, that inhibit T cell CD3z expression and cytokine production [119] . Importantly, NO can then react with superoxide to produce more harmful RNS, such as PNT that is synthesized in PMN-MDSCs by the action of gp91 phox and NOS3 [133] . PNT inhibits T cell responses through the following: 1) inducing T cell apoptosis via the nitration of tyrosine residues, thus impairing protein tyrosine phosphorylation [136] ; 2) disrupting the conformational flexibility of the TCR-MHC/peptide binding by nitrating/nitrosylating the TCR and MHC [137, 138] ; and 3) preventing the recruitment of T cells while promoting the migration of MDSCs into tumors through the nitration of chemokines, such as CCL2 and CCL5, or chemokine receptors, such as CXCR4 [139, 140] .
Given that the arginine-catabolizing enzymes arginase 1, NOS2, and NOS3 represent major regulatory pathways by which suppressive myeloid cells can block T cell anti-tumor immune responses, this certainly provides exciting opportunities for developing strategies to target these mechanisms. We [141] and others [139, 142] have recently reviewed the main therapeutic approaches used to manipulate the regulators of arginine metabolism in MDSCs.
Tryptophan metabolism, dependent on the activity of IDO, is another pathway that drives MDSC-mediated inhibition of immune responses [143, 144] . MDSCs decrease the levels of tryptophan in the external environment by inducing IDO, which catabolizes this essential amino acid to N-formylkynurenine. As is the case with arginine, tryptophan starvation arrests T cell growth via the GCN2 pathway [145] . MDSCs can also suppress T cell responses by sequestering cysteine via consuming cystine and not exporting cysteine back into the microenvironment [146] .
Emerging work from several groups, including ours, suggests the role of other energy metabolic pathways, besides that of amino acid metabolism, in the regulation of tumor-associated MDSCs. Bone marrow-derived MDSCs, generated in the presence of GM-CSF and IL-6, display an increased central carbon metabolism, including glycolysis, glutaminolysis, and TCA cycle activity. AMPK is also activated by these in vitro culture conditions. Although the association between AMPK and a specific metabolic pathway has not been uncovered, inhibition of AMPK activity reduces the immunosuppressive mechanisms and function of MDSCs [147] . Another study has shown that MDSCs, differentiated into M2 but not M1 myeloid lineage, have an abolished glycolytic activity. Mechanistically, deficiency of the NAD-dependent deacetylase sirtuin 1 impairs the differentiation of immunosuppressive M2-type MDSCs and switches them into proinflammatory M1-type cells associated with tumor-killing activity, effects that are dependent on the mTOR/HIF-1a pathway [148] . In accordance with this study, HIF-1a is known as a critical regulator of the differentiation and function of MDSCs controlling their alternative differentiation toward M2-type cells in the tumor microenvironment [149] . Additionally, HIF-1a critically controls the hypoxia-induced expression of PD-L1, not only in MDSCs but also in TAMs and DCs [150] . As such, the blockade of HIF-1a or PD-L1 overcomes the MDSC-mediated T cell suppression [149, 150] . In this context, a recent study has revealed that hypoxia increases CD45 tyrosine phosphatase activity in tumor-infiltrating myeloid cells. This results in a selective down-regulation of STAT3 activity, an effect that facilitates the differentiation of MDSCs into TAMs [151] . We have recently investigated for the first time the metabolic characteristics of tumor-infiltrating MDSCs relative to peripheral MDSCs and normal myeloid cells. Of interest, tumor-infiltrating MDSCs preferentially use FAO over glycolysis as a primary source of energy. This coincides with an increased mitochondrial mass, key FAO-associated genes (CPT1, acyl-CoA dehydrogenase, PGC1b, and HADHA), and oxygen consumption rate. These metabolic responses appears to be activated in both M-MDSCs and PMN-MDSCs. Likewise, human MDSCs also take up high amounts of fatty acids and increase the expression of FAO enzymes (CPT1 and HADHA) [152, 153] . More recently, PMN-MDSC have been shown to overexpress lectin-type oxidized LDLR 1, which identifies a subpopulation of ER-stressed, immunosuppressive PMN-MDSCs in cancer patients [154] . Importantly, FAO inhibition restrains the immunoregulatory pathways and functions in tumor-infiltrating MDSCs. Accordingly, FAO inhibition results in a T cell-dependent delay in tumor growth and synergistically decreases tumor growth when combined with chemotherapy and adoptive cellular therapy [152, 153] . However, the factors underlying the induction of FAO and the molecular mechanisms linking FAO with the regulatory pathways in tumor-infiltrating MDSCs and their subtypes remain to be determined.
PERSPECTIVE AND CONCLUSIONS
Accumulating evidence suggests that the regulated cellular metabolism essentially dictates the phenotype and function of immune cells. In most cases, metabolic reprogramming is triggered by key receptor signaling events, together with metabolite availability. Interestingly, immune cells can opt for the metabolic features that allow them to meet their functional demands under the conditions present in the surrounding microenvironment (Fig. 2) . A well-characterized example of this is the differential metabolic fates in M1 and M2 Mf. Proinflammatory M1 Mf are often found in hypoxic regions clearing infections. Thus, glycolysis provides a rapid means for the generation of ATP and biosynthetic intermediates. Additionally, the halting of the mitochondrial respiration, coupled with NADPH derived from the PPP, facilitates the production of microbicidal ROS. On the contrary, anti-inflammatory M2 Mf are involved in longer-term activities, such as tissue healing, and, therefore, depend on FAO and OXPHOS as a more efficient source of energy. In this context, recent findings point out that other anti-inflammatory myeloid subsets, such as tolerogenic DCs and tumor-infiltrating MDSCs, may also use FAO to support cellular function and survival. This makes it plausible that there is a causal association between OXPHOS fueled by lipid catabolism and the development into myeloid cells with an immunosuppressive signature. However, it is imperative to mention that the underlying mechanisms of how cellular metabolism supports the tolerogenic functions of DCs and MDSCs are only beginning to be precisely elucidated. Likewise, the metabolic characteristics of the different subpopulations of these myeloid cells, particularly those harvested from diseased versus healthy tissues, have yet to be determined.
Given the complexity of diseased microenvironments, it is important to consider the metabolic interaction and competition for nutrients and other resources, such as oxygen, between different cellular players. For instance, lactate generated by tumor cells as a glycolytic byproduct drives the expansion and function of MDSCs and TAMs [155, 156] . In addition, as discussed, the deprivation of the external environment of amino acids (arginine, tryptophan, and cysteine), essential for T cells by the action of enzymes, expressed by tumor and/or myeloid cells, shuts down several aspects of T cell anti-tumor capacity. Likewise, glucose consumption by the highly glycolytic tumor cells constrains T cell anti-tumor immunity, an effect that can be reversed through increasing glucose availability in the tumor microenvironment using a checkpoint blockade that directly impairs the glycolytic flux in tumor cells [157] . Accordingly, it is of interest to determine whether these metabolically harsh conditions, as in tumors, are what drive some myeloid cells, such as MDSCs, to adopt lipid metabolism rather than glycolysis and whether similar metabolic adaptations would be seen in other chronic inflammatory conditions, such as infections.
Lastly, manipulation of the metabolism of myeloid cells holds great potential for multiple therapeutic applications. Based on the discussions above, it is becoming increasingly clear that metabolic interventions are capable of promoting or inhibiting immune responses. It will be exciting to determine specifically which metabolic nodes could be targeted to switch tolerogenic cells to immunogenic ones or vice versa. Such findings will allow for the development of novel small molecules or the repurposing of existing metabolic drugs for the treatment of conditions, such as cancer, infections, GVHD, and autoimmune diseases. It is also more likely that these new drugs will be most effective when combined with already existing interventions to promote the 
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